PSI TFA
Based on 2 publication(s) in Google Scholar
PSI (TFA) is a potent proteasome inhibitor. PSI (TFA) inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI (TFA) can be used for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C34H51F3N4O10
- Peso molecular:732.78
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) PSI TFA
More
Actividad biológica
CC50: 205 nM (BJAB cells); 190 nM (Ramos cells); 22.0 nM (BC3 cells); 53.0 nM (BCBL1 cells)[1]
PSI (TFA) (24 h) inhibits the proliferation with CC50 values of 205, 190, 22.0, 53.0 nM for BJAB, Ramos, BC3, BCBL1 cells, respectively)[1].
PSI (TFA) (50 nM; 6 h) increases caspase-3/7 activity by 8-fold compared with control[1].
PSI (TFA) (50 nM; 6 h) decreases the transcriptional activity of NF-κB by 52%[1].
PSI (TFA) (1, 5 nM; 3 days) inhibits the growth of BC3 cells at a high concentration (5 nM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BC3, BCBL1, Ramos, BJAB cells
-
Concentration:
-
Incubation Time:24 h
-
Result:Inhibited the proliferation of primary effusion lymphoma (PEL) cells at low nanomolar concentrations (CC50 values of 205, 190, 22.0, 53.0 nM for BJAB, Ramos, BC3, BCBL1 cells, respectively).
-
Cell Line:HBL6 cells
-
Concentration:50 nM
-
Incubation Time:6 h
-
Result:Decreased the NF-κB activity by 52%.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
Peso molecular 732.78
-
Fòrmula C34H51F3N4O10
-
Synonyms
Proteasome Inhibitor 1 TFA; Z-Ile-Glu(OtBu)-Ala-Leu-CHO TFA
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Br J Pharmacol
Fenofibrate potentiates the therapeutic efficacy of EZH2 inhibitors on melanoma via TRIM21- and OTUD4-mediated EZH2 ubiquitination. [Abstract]2026 Jun;183(11):2675-2694. PMID: 41652905
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)